EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Multi‐omics Analysis Reveals the Correlation of Gut Microbiota and Metabolites With Thalidomide Treatment for Chemotherapy‐Induced Nausea and Vomiting in Small Cell Lung Cancer

Qiang-Guo Sun, Dan Zang, Yu Xin, Jia Cui, Xu Han, Jun Chen iD

Biotechnology Journal · 2026

DOI: 10.1002/biot.70228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Journal, 2026. Verfasst von Qiang-Guo Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China. Hauptthemen laut MEDLINE: Thalidomide, Small Cell Lung Carcinoma, Lung Neoplasms, Gastrointestinal Microbiome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small cell lung cancer (SCLC) is a highly aggressive malignancy, and chemotherapy frequently causes nausea and vomiting, which can impair treatment tolerance. Because thalidomide (THD) has shown potential clinical benefit in alleviating nausea and anorexia, we investigated whether its effects might be associated with changes in gut microbial composition and metabolite profiles. Fecal samples were collected from patients with SCLC and categorized into THD‐treated and control groups. Metagenomic sequencing and nontargeted metabolomic profiling were performed to characterize microbial composition and metabolic signatures. THD treatment was also associated with higher microbial alpha diversity and increased abundance of genera such as Eubacterium and Prevotella . Metabolomic analysis identified several differential metabolites, including hydrogenated MDI, becocalcidiol, β‐octylglucoside, and azelaic acid. Collectively, these findings suggest that the gut microbiota‐metabolite axis may be associated with the potential effects of THD on CINV and anorexia in patients with SCLC. The identified microbial taxa and metabolites may serve as candidate biomarkers or potential therapeutic targets, although further validation in larger studies is necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThalidomideSmall Cell Lung CarcinomaLung NeoplasmsGastrointestinal MicrobiomeNauseaVomitingHumansMultiomicsMaleFemaleMiddle AgedAgedMetabolomeMetabolomicsAntineoplastic Agents

Stichwörter der Autor:innen

gut microbiotametabolitessmall cell lung cancerthalidomide

Substanzen

ThalidomideAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China.

ORCID-Profile: Jun Chen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Sun, Q. G., Zang, D., Xin, Y., Cui, J., Han, X., & Chen, J. (2026). Multi‐omics Analysis Reveals the Correlation of Gut Microbiota and Metabolites With Thalidomide Treatment for Chemotherapy‐Induced Nausea and Vomiting in Small Cell Lung Cancer. Biotechnology Journal. https://doi.org/10.1002/biot.70228

Vancouver

Sun QG, Zang D, Xin Y, Cui J, Han X, Chen J. Multi‐omics Analysis Reveals the Correlation of Gut Microbiota and Metabolites With Thalidomide Treatment for Chemotherapy‐Induced Nausea and Vomiting in Small Cell Lung Cancer. Biotechnology Journal. 2026. doi:10.1002/biot.70228

BibTeX
@article{Sun2026,
  author = {Sun, Qiang-Guo and Zang, Dan and Xin, Yu and Cui, Jia and Han, Xu and Chen, Jun},
  title = {Multi‐omics Analysis Reveals the Correlation of Gut Microbiota and Metabolites With Thalidomide Treatment for Chemotherapy‐Induced Nausea and Vomiting in Small Cell Lung Cancer},
  journal = {Biotechnology Journal},
  year = {2026},
  doi = {10.1002/biot.70228}
}
Kostenlos starten →